Tropicamide vs Ipratropium — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Anticholinergic

Tropicamide

Brand: Mydriacyl

First FDA approval: 1959-04-01

Anticholinergic

Ipratropium

Brand: Atrovent

First FDA approval: 2001-09-27

Lowest NADACAcquisition cost floor across all NDCs

$0.498Per unit

$0.099Per unit

Average NADACAcross all dosage forms and strengths

$0.897Up to $2.67

$1.07Up to $22.77

Generic manufacturersActive ANDA holders — FDA Orange Book

77 total ANDAs filed

1016 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$12388Full year

$244.7MFull year

Part D claims (CY24)Total fills, all strengths

1K1K beneficiaries

3.6M1.6M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$10Per claim, all NDCs

$69Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

335Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes7 manufacturers

Yes10 manufacturers